The General Hospital Corporation

United States of America

Back to Profile

1-100 of 2,067 for The General Hospital Corporation Sort by
Query
Patent
United States - USPTO
Excluding Subsidiaries
Aggregations Reset Report
Date
New (last 4 weeks) 26
2024 July (MTD) 4
2024 June 22
2024 May 30
2024 April 15
See more
IPC Class
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons 246
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca 146
A61K 9/00 - Medicinal preparations characterised by special physical form 109
A61K 39/00 - Medicinal preparations containing antigens or antibodies 104
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides 103
See more
Status
Pending 622
Registered / In Force 1,445
Found results for  patents
  1     2     3     ...     21        Next Page

1.

Biosensors in Human Gut Organoids

      
Application Number 18432439
Status Pending
Filing Date 2024-02-05
First Publication Date 2024-07-04
Owner
  • The General Hospital Corporation (USA)
  • Massachusetts Institute of Technology (USA)
Inventor
  • Fasano, Alessio
  • Lu, Timothy K.
  • Senger, Stefania
  • Inda, Maria Eugenia

Abstract

Ex vivo monolayer models of human interstinal epithelia that express sensors, and methods of use thereof for evaluation of the effects of test compounds on the human gut.

IPC Classes  ?

  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

2.

Systems and Methods for Delivery of Light With Increased Omnidirectionality

      
Application Number 17905806
Status Pending
Filing Date 2021-03-12
First Publication Date 2024-07-04
Owner
  • The General Hospital Corporation (USA)
  • Massachusetts Institute of Technology (USA)
Inventor
  • Yun, Seok-Hyun
  • Dannenberg, Paul

Abstract

A laser microparticle for generating laser light with high omnidirectionality, including: an optical cavity including an active gain material capable of supporting one or more lasing cavity modes: and an optical scattering element which is incorporated into the optical cavity and configured to change a radiation pattern of the one or more lasing cavity modes to increase omnidirectionality of the radiation pattern, the size of the microparticle being less than 10 pm in each dimension.

IPC Classes  ?

  • H01S 5/10 - Construction or shape of the optical resonator

3.

COMPOSITIONS AND METHODS FOR PREVENTING OR DELAYING PUBERTY IN PREPUBESCENT NON-HUMAN ANIMALS AND HUMANS

      
Application Number 18283556
Status Pending
Filing Date 2022-03-22
First Publication Date 2024-07-04
Owner The General Hospital Corporation (USA)
Inventor
  • Donahoe, Patricia K.
  • Pepin, David

Abstract

The present invention relates to compositions and methods of reducing fertility and/or preventing puberty in prepubescent non-human subjects (e.g., kittens and puppies) by administering a composition comprising a vector comprising a nucleic acid encoding a Mullerian Inhibiting Substance (MIS) operatively linked to one or more regulatory elements. In some embodiments, administration is via a single or multiple injection. Other aspects relate to method and compositions for delaying puberty in a human female subject by administering a recombinant human MIS variant protein.

IPC Classes  ?

  • C07K 14/575 - Hormones
  • A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61P 15/00 - Drugs for genital or sexual disorders; Contraceptives
  • C12N 15/86 - Viral vectors
  • C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

4.

METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS

      
Application Number 18540207
Status Pending
Filing Date 2023-12-14
First Publication Date 2024-07-04
Owner The General Hospital Corporation (USA)
Inventor Faustman, Denise L.

Abstract

The invention features methods of producing compositions enriched in Tregs and methods for treating immunological disorders using these compositions. The invention also features methods for producing compositions enriched in lymphocytes and depleted of Tregs and the use of these compositions in the treatment of proliferative disorders.

IPC Classes  ?

  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

5.

AAV Capsids and Uses Thereof

      
Application Number 18288460
Status Pending
Filing Date 2022-04-27
First Publication Date 2024-06-27
Owner The General Hospital Corporation (USA)
Inventor
  • Musolino, Patricia L.
  • Maguire, Casey A.
  • Hudry, Eloise
  • Hanlon, Killian S.

Abstract

Described herein are capsid peptides that mediated efficient AAV transduction of the brain vasculature, mainly endothelial cells and pericytes, as well as smooth muscle cells, compositions (including AAV), and methods of using the same. Embodiments of the invention encompass AAV capsid proteins comprising an amino acid sequence that comprises at least four, at least five, or at least six contiguous amino acids from the sequence PRPPSTH (SEQ ID NO: 1); MAEPGAR (SEQ ID NO: 2); SQDPSTL (SEQ ID NO: 3); or MLYADNT (SEQ ID NO: 4).

IPC Classes  ?

  • C12N 15/86 - Viral vectors
  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

6.

METHOD AND APPARATUS FOR TISSUE EXPANSION

      
Application Number 18335756
Status Pending
Filing Date 2023-06-15
First Publication Date 2024-06-27
Owner The General Hospital Corporation (USA)
Inventor
  • Anderson, Richard Rox
  • Willey, Andrea
  • Farinelli, William A.

Abstract

Exemplary embodiments of the present disclosure provide method and apparatus for facilitating stretching of a biological tissue by forming a plurality of micro-slits in the tissue. Each micro-slit can be less than about 2 mm or less than about 1.5 mm long, or even less than about 1 mm, such that small gaps that can heal quickly can be formed when the tissue is stretched. The micro-slits can be formed using a plurality of cutting arrangements or an ablative laser. The micro-slits can be formed in various patterns, including staggered rows, circular or spiral patterns, or random patterns.

IPC Classes  ?

  • A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
  • A61B 17/3209 - Incision instruments
  • A61B 17/322 - Skin grafting apparatus
  • A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
  • A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F 2/10 - Hair or skin implants

7.

GENERATING A MOTION-CORRECTED MAGNETIC RESONANCE IMAGE DATASET

      
Application Number 18521089
Status Pending
Filing Date 2023-11-28
First Publication Date 2024-06-27
Owner
  • Siemens Healthcare GmbH (Germany)
  • The General Hospital Corporation (USA)
Inventor
  • Polak, Daniel
  • Splitthoff, Daniel Nicolas
  • Cauley, Stephen Farman

Abstract

A method for generating a motion-corrected MR image dataset of a subject includes: acquiring k-space data of an MR image of a subject in an imaging sequence; acquiring at least two low-resolution scout images of the subject interleaved with the k-space data of the imaging sequence; comparing the scout images with one another in order to detect and/or to estimate subject motion between the scout images; and reconstructing a motion-corrected MR image dataset from the k-space data acquired in the imaging sequence. The reconstruction process includes: estimating the motion trajectory of the subject by comparing the k-space data with at least one of the low-resolution scout images; and estimating the motion-corrected image dataset using the estimated motion trajectory, wherein the estimations involve minimizing the data consistency error between the acquired k-space data and a forward model described by an encoding operator.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G06T 7/20 - Analysis of motion
  • G06T 7/30 - Determination of transform parameters for the alignment of images, i.e. image registration
  • G06T 11/00 - 2D [Two Dimensional] image generation

8.

IL2 TETHERED TO ITS RECEPTOR IL2RBETA AND PORE-FORMING PROTEINS AS A PLATFORM TO ENHANCE IMMUNE CELL ACTIVITY

      
Application Number 18288519
Status Pending
Filing Date 2022-04-27
First Publication Date 2024-06-27
Owner The General Hospital Corporation (USA)
Inventor
  • Chen, Sumei
  • Cotten, Joseph F.
  • Jounaidi, Youssef
  • Miller, Keith
  • Forman, Stuart

Abstract

Described herein are immune cells (e.g., natural killer (NK), T cells) expressing a chimeric protein comprising IL2 and IL2Rβ (e.g., CIRB), a chimeric protein comprising IL2, IL2Rβ and IL21R (e.g., CIRB21), a chimera protein comprising IL2, IL2Rβ, and CD28 (e.g., CIRB28), or a combination thereof, and comprising a nucleic acid encoding a pore-forming protein, and methods of using such immune cells for treating a subject (e.g., a subject having cancer, graft-versus-host disease (GVHD), or an autoimmune disease. Expression of the pore-forming protein can be induced to promote destruction of immune cells expressing CIRB, CIRB21, CIRB28, or a combination thereof.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K 41/17 - Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
  • A61P 35/00 - Antineoplastic agents
  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • C07K 14/55 - IL-2
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C07K 14/715 - Receptors; Cell surface antigens; Cell surface determinants for interferons
  • C12N 15/86 - Viral vectors

9.

METHOD FOR ACQUIRING A MAGNETIC RESONANCE IMAGE DATASET AND GENERATING A MOTION-CORRECTED IMAGE DATASET

      
Application Number 18519741
Status Pending
Filing Date 2023-11-27
First Publication Date 2024-06-20
Owner
  • Siemens Healthcare GmbH (Germany)
  • The General Hospital Corporation (USA)
Inventor
  • Polak, Daniel
  • Splitthoff, Daniel Nicolas
  • Cauley, Stephen Farman

Abstract

A method is provided for acquiring a magnetic resonance image dataset of an object, using an imaging protocol in which several k-space lines are acquired in one echo train, wherein the echo train may include one or several sub echo trains, and wherein the imaging protocol includes a plurality of echo trains. Within the method, a set of additional k-space lines within a central region of k-space is acquired a number of times per echo train, wherein the number is greater than 1, in order to detect movement of the object during the echo train. The sets of additional k-space lines are acquired at pre-determined positions within the echo trains. The disclosure is also directed to a method for generating a motion-corrected magnetic resonance image dataset from the dataset thus acquired, a magnetic resonance imaging apparatus, and a computer program.

IPC Classes  ?

  • G01R 33/48 - NMR imaging systems
  • G01R 33/385 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using gradient magnetic field coils
  • G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities

10.

USE OF EXTENSIVELY HYDROLYSED PROTEIN

      
Application Number 18572580
Status Pending
Filing Date 2022-06-24
First Publication Date 2024-06-20
Owner
  • MJN U.S. Holdings LLC (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Fasano, Alessio
  • Gross, Gabriele
  • Manurung, Sarmauli Irianti
  • Senger, Stefania
  • Van Tol, Eric Alexander Franciscus

Abstract

The present application relates to extensively hydrolysed protein, and compositions comprising extensively hydrolysed protein, for use in reducing the risk of intestinal inflammation, reducing the risk of intestinal tissue damage, and/or improving gut barrier function, in an infant.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

11.

HIGHLY SENSITIVE IN VITRO ASSAYS TO DEFINE SUBSTRATE PREFERENCES AND SITES OF NUCLEIC-ACID BINDING, MODIFYING, AND CLEAVING AGENTS

      
Application Number 18402501
Status Pending
Filing Date 2024-01-02
First Publication Date 2024-06-20
Owner The General Hospital Corporation (USA)
Inventor
  • Joung, J. Keith
  • Pattanayak, Vikram
  • Petri, Karl

Abstract

Methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.

IPC Classes  ?

  • C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

12.

SYSTEM AND METHOD FOR INVERSE TREATMENT PLANNING FOR RADIATION THERAPY

      
Application Number 18549697
Status Pending
Filing Date 2022-03-08
First Publication Date 2024-06-20
Owner
  • The General Hospital Corporation (USA)
  • Tilburg University (Netherlands)
Inventor
  • Bortfeld, Thomas
  • Ajdari, Ali
  • Ten Eikelder, Stefan
  • Den Hertog, Dick

Abstract

Systems and methods are provided for determining a treatment plan for a radiation therapy system. The method includes dividing a three-dimensional volume of a patient into a grid of dose voxels, wherein at least a portion of said dose voxels are designated to belong to at least one target or to at least one critical structure. The method also includes modeling an ionizing radiation dose as delivered by a plurality of beamlets each having a beamlet fluence, to create a modeled radiation dose fluence map. The method also includes determining a voxel-based fluence map optimization (FMO) model for the modeled radiation dose a fluence map. The method also includes determining a conic optimization formulation for the FMO model to create a determined conic optimization solution and generating an optimized fluence map by updating the modeled radiation dose fluence map with the determined conic optimal fluence map.

IPC Classes  ?

  • A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
  • G06F 17/11 - Complex mathematical operations for solving equations

13.

PHOTOCHEMICAL TISSUE BONDING CLAMP AND IRRADIATION CHAMBER AND METHOD OF USE THEREOF

      
Application Number 18555407
Status Pending
Filing Date 2022-04-13
First Publication Date 2024-06-20
Owner The General Hospital Corporation (USA)
Inventor Winograd, Jonathan M.

Abstract

A device, kit, and method for performing photochemical tissue bonding on a biological structure is provided. The device includes a first channel, a second channel, and an open window. The first channel is sized to receive a first portion of the biological structure, the second channel is sized to receive a second portion of the biological structure. The open window is positioned between the first channel and the second channel so that a third portion of the biological structure is exposed within the open window when the first channel receives the first portion and the second channel receives the second portion, where photochemical tissue bonding may be applied to the third portion.

IPC Classes  ?

  • A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets
  • A61B 17/11 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for performing anastomosis; Buttons for anastomosis
  • A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves

14.

SORTING PARTICLES IN A MICROFLUIDIC DEVICE

      
Application Number 18595920
Status Pending
Filing Date 2024-03-05
First Publication Date 2024-06-20
Owner The General Hospital Corporation (USA)
Inventor
  • Kapur, Ravi
  • Smith, Kyle C.
  • Toner, Mehmet

Abstract

A microfluidic device includes a particle sorting region having a first, second and third microfluidic channels, a first array of islands separating the first microfluidic channel from the second microfluidic channel, and a second array of islands separating the first microfluidic channel from the third microfluidic channel, in which the island arrays and the microfluidic channels are arranged so that a first fluid is extracted from the first microfluidic channel into the second microfluidic channel and a second fluid is extracted from the third microfluidic channel into the first microfluidic channel, and so that particles are transferred from the first fluid sample into the second fluid sample within the first microfluidic channel.

IPC Classes  ?

  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • G01N 1/40 - Concentrating samples
  • G01N 15/00 - Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
  • G01N 15/01 - specially adapted for biological cells, e.g. blood cells (investigating sedimentation of particle suspensions in blood G01N 15/05)
  • G01N 15/02 - Investigating particle size or size distribution
  • G01N 15/06 - Investigating concentration of particle suspensions
  • G01N 15/14 - Electro-optical investigation
  • G01N 15/149 - specially adapted for sorting particles, e.g. by their size or optical properties

15.

CONCENTRATING PARTICLES IN A MICROFLUIDIC DEVICE

      
Application Number 18595927
Status Pending
Filing Date 2024-03-05
First Publication Date 2024-06-20
Owner The General Hospital Corporation (USA)
Inventor
  • Kapur, Ravi
  • Smith, Kyle C.
  • Toner, Mehmet

Abstract

A microfluidic device includes: a first microfluidic channel; a second microfluidic channel extending along the first microfluidic channel; and a first array of islands separating the first microfluidic channel from the second microfluidic channel, in which each island is separated from an adjacent island in the array by an opening that fluidly couples the first microfluidic channel to the second microfluidic channel, in which the first microfluidic channel, the second microfluidic channel, and the islands are arranged so that a fluidic resistance of the first microfluidic channel increases relative to a fluidic resistance of the second microfluidic channel along a longitudinal direction of the first microfluidic channel such that, during use of the microfluidic device, a portion of a fluid sample flowing through the first microfluidic channel passes through one or more of the openings between adjacent islands into the second microfluidic channel.

IPC Classes  ?

  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • G01N 1/40 - Concentrating samples
  • G01N 15/00 - Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
  • G01N 15/01 - specially adapted for biological cells, e.g. blood cells (investigating sedimentation of particle suspensions in blood G01N 15/05)
  • G01N 15/02 - Investigating particle size or size distribution
  • G01N 15/06 - Investigating concentration of particle suspensions
  • G01N 15/14 - Electro-optical investigation
  • G01N 15/149 - specially adapted for sorting particles, e.g. by their size or optical properties

16.

Minimal Human-Derived Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules

      
Application Number 18511486
Status Pending
Filing Date 2023-11-16
First Publication Date 2024-06-13
Owner The General Hospital Corporation (USA)
Inventor
  • Joung, J. Keith
  • Cabeceiras, Peter

Abstract

Described herein are virus-like particles (VLPs) and minimal human-derived virus-like particles (mhVLPs), comprising a membrane comprising a phospholipid bilayer with one or more human-derived envelope glycoproteins (env) on the external side. Optionally, a biomolecule cargo is disposed in the core of the VLP or mhVLP on the inside of the membrane. Preferably, the mhVLPs do not comprise any exogenous virally derived proteins, e.g., proteins from viral gag, pro, or pol, or other viral proteins that reside inside of enveloped particles (unless the cargo comprises the viral protein(s)). In some embodiments, the mhVLPs do not comprise any human endogenous retroviral (HERV) proteins other than the env (hENV), e.g., do not comprise gag, pol, or pro that was exogenously introduced into producer cells. In some embodiments, the VLPs include a targeting domain, either fused at the N or C terminus or internally into the hENV, or as a separate membrane-anchored targeting domain. Also described are methods of use of the VLPs or mhVLPs for delivery of the biomolecule cargo to cells.

IPC Classes  ?

  • A61K 9/51 - Nanocapsules
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/86 - Viral vectors

17.

FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS

      
Application Number 18548580
Status Pending
Filing Date 2022-03-02
First Publication Date 2024-06-13
Owner
  • THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE BROAD INSTITUTE, INC. (USA)
Inventor
  • Hergenrother, Paul J.
  • Parker, Erica Nicole
  • Hung, Deborah
  • Serrano-Wu, Michael
  • Lee, Katie Kyungae

Abstract

A FabI inhibitor called fabimycin that has impressive activity against >200 clinical isolates of E. coli, K. pneumoniae, and A. baumannii. Fabimycin has activity in multiple mouse models of infection caused by Gram-negative bacteria, including a model of urinary tract infection. Fabimycin has translational promise, and its discovery provides data indicating that antibiotics whose spectrum of activity is restricted to Gram-positive bacteria can be systematically modified to accumulate in Gram-negative bacteria and be effective against these problematic pathogens.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 47/02 - Inorganic compounds
  • A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
  • A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
  • A61K 47/38 - Cellulose; Derivatives thereof
  • A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
  • A61P 31/04 - Antibacterial agents
  • C07D 471/20 - Spiro-condensed systems

18.

SYSTEMS AND METHODS FOR INCREASING METABOLIC RATES

      
Application Number 18554536
Status Pending
Filing Date 2022-04-11
First Publication Date 2024-06-13
Owner The General Hospital Corporation (USA)
Inventor
  • Manstein, Dieter
  • Wang-Evers, Michael
  • Salma, Nunciada

Abstract

A treatment system can include an energy source configured to thermally damage skin tissue of a subject, a user input device configured to receive a user input, and a computing device that can be configured to receive, from the user input device, the user input indicative of one or more operational parameters of the energy source based on the user input, control the energy source according to the one or more operational parameters to cause the energy source to thermally damage the skin tissue by creating a plurality of treatment regions within a target region of the skin tissue to increase a basal metabolic rate of the subject, wherein the target region includes a non-treatment portion that is interspersed among the treatment regions.

IPC Classes  ?

  • A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
  • A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
  • A61B 18/14 - Probes or electrodes therefor

19.

Virus-like Particles with Programmable Tropism and Methods of Use Thereof for Delivery to Cells

      
Application Number 18511416
Status Pending
Filing Date 2023-11-16
First Publication Date 2024-06-13
Owner The General Hospital Corporation (USA)
Inventor
  • Joung, J. Keith
  • Cabeceiras, Peter

Abstract

Described herein are programmable tropism virus-like particles (ptVLPs), comprising a membrane comprising a phospholipid bilayer with one or more wild-type or mutant/truncated virus-derived glycoproteins on the external side. The virus-derived envelope glycoprotein(s) can optionally be fused directly to a targeting domain (e.g., peptide, single chain variable fragment (scFv), nanobody, fibronectin type 3 domain (FN3), arginylglycylaspartic acid motif (RGD), single variable domain on a heavy chain/nanobody (VHH), variable domain of new antigen receptor (VNAR), darpin, or other targeting ligand), and/or can be present in combination with a membrane-anchored targeting domain. A biomolecule cargo (preferably fused to a membrane recruitment domain, such as a Pleckstrin homology domain) can be disposed in the core of the ptVLP. Preferably, the ptVLP does not comprise a protein from any human endogenous or exogenous viral gag, pro, pol, or other viral proteins that reside inside of enveloped particles.

IPC Classes  ?

  • C12N 15/86 - Viral vectors
  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof

20.

Minimal Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules

      
Application Number 18511459
Status Pending
Filing Date 2023-11-16
First Publication Date 2024-06-13
Owner The General Hospital Corporation (USA)
Inventor
  • Joung, J. Keith
  • Cabeceiras, Peter

Abstract

Described herein are minimal virus-like particles (mVLPs), comprising a membrane comprising a phospholipid bilayer with one or more ectodomain-truncated VSV envelope glycoproteins on the external side; and a biomolecule cargo disposed in the core of the mVLP on the inside of the membrane. Preferably, the mVLPs do not comprise a protein from viral gag, pro, pol, or other viral proteins that reside inside of enveloped particles. Also described are methods of use of the mVLPs for delivery of the biomolecule cargo to cells.

IPC Classes  ?

  • C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/86 - Viral vectors

21.

Supercharged Biovesicles and Methods of Use Thereof

      
Application Number 18287861
Status Pending
Filing Date 2022-04-22
First Publication Date 2024-06-06
Owner The General Hospital Corporation (USA)
Inventor
  • Breyne, Koen
  • Ughetto, Stefano
  • Breakefield, Xandra O.

Abstract

Provided herein are compositions comprising positively supercharged proteins (+scProteins), membrane-bound vesicles (EV, VLP, and/or LVV membranes), and cargo, and methods of use thereof to deliver the cargo to the intracellular space of target cells. Also provided are reporter constructs that can be used to detect genome editing events, and methods of use thereof.

IPC Classes  ?

  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • C12N 15/86 - Viral vectors
  • C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

22.

AUTOCALIBRATED MULTI-SHOT MAGNETIC RESONANCE IMAGE RECONSTRUCTION WITH JOINT OPTIMIZATION OF SHOT-DEPENDENT PHASE AND PARALLEL IMAGE RECONSTRUCTION

      
Application Number 18552970
Status Pending
Filing Date 2022-03-28
First Publication Date 2024-06-06
Owner The General Hospital Corporation (USA)
Inventor
  • Cauley, Stephen
  • Setsompop, Kawin
  • Wald, Lawrence
  • Bilgic, Berkin

Abstract

Images are reconstructed from k-space acquired with a magnetic resonance imaging (“MRI”) system using a multi-shot pulse sequence. In each iteration, a phase-aware image reconstruction, a data-consistency update across all shots or subsets of data, and a relative phase estimation across the reconstructed images for each shot are performed. In this way. the reconstruction framework recasts the problem as an iterative relative phase estimation problem, which allows for the use relative phase estimation techniques. Through an iterative search, an artifact-free combined image and the smooth relative phase between each shot in the multi-shot k-space data can be jointly estimated.

IPC Classes  ?

  • G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
  • G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
  • G06T 7/00 - Image analysis
  • G06T 11/00 - 2D [Two Dimensional] image generation

23.

METHODS AND COMPOSITIONS FOR DETECTION OF TUMOR DNA

      
Application Number 18285103
Status Pending
Filing Date 2022-03-30
First Publication Date 2024-06-06
Owner
  • The Broad Institute, Inc. (USA)
  • Massachusetts Institute of Technology (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Adalsteinsson, Viktor A.
  • Hacohen, Nir
  • Bhatia, Sangeeta N.
  • Patel, Sahil
  • An, Zhenyi

Abstract

This disclosure provides a method and compositions for substantially increasing the concentration of DNA in macrophages of a patient. By administering to a patient one or more agents which prevent the activity of deoxyribonucleases within lysosomes of macrophages, degradation of DNA phagocytosed by macrophages is temporarily blocked, permitting its accumulation. This strategy has the potential to enhance the detection of genetic biomarkers from cells typically phagocytosed by macrophages, such as tumor cells, and thus has applications for early or residual detection of cancer.

IPC Classes  ?

  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
  • A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
  • A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

24.

APPARATUS, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR OBTAINING TISSUE SAMPLES

      
Application Number 18527531
Status Pending
Filing Date 2023-12-04
First Publication Date 2024-06-06
Owner The General Hospital Corporation (USA)
Inventor
  • Tearney, Guillermo J.
  • Gardecki, Joseph
  • Liang, Chia-Pin

Abstract

Apparatus and method can be provided for obtaining at least one anatomical sample. For example, it is possible to provide and insert a housing into a body or provided on a hydrated anatomical structure. Further, with a source, it is possible to emit an electromagnetic radiation which causes at least the anatomical sample(s) to attach to at least one portion of the housing. A compound can be provided on a surface of the housing, and the source provides the radiation to the compound and changes properties thereof to be adhesive. The source can provide the radiation to the housing, and can change properties of a surface thereof to be adhesive. A component can be provided on a surface of the anatomical structure, and the source provides the radiation to the compound and changes properties thereof to be adhesive.

IPC Classes  ?

  • A61B 10/04 - Endoscopic instruments
  • A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 10/02 - Instruments for taking cell samples or for biopsy
  • A61N 5/06 - Radiation therapy using light

25.

COMPACT SIGNAL FEATURE EXTRACTION FROM MULTI-CONTRAST MAGNETIC RESONANCE IMAGES USING SUBSPACE RECONSTRUCTION

      
Application Number 18552972
Status Pending
Filing Date 2022-03-28
First Publication Date 2024-06-06
Owner The General Hospital Corporation (USA)
Inventor
  • Setsompop, Kawin
  • Dong, Zijing
  • Wang, Fuyixue

Abstract

Signal feature data are efficiently extracted from multi-contrast magnetic resonance images and applied to one or more machine learning algorithms to generate tissue feature data that indicate one or more tissue properties of a tissue depicted in the original multi-contrast images. Compact signal feature map data are extracted from the multi-contrast image data by generating or otherwise constructing subspace bases from prior signal data. and coefficient maps of the subspace bases are generated using a subspace reconstruction. A machine learning algorithm can be implemented to transform the signal feature maps to target tissue property parameters and/or to classify different tissue types.

IPC Classes  ?

  • G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
  • G06T 7/00 - Image analysis

26.

DISTORTION-FREE DIFFUSION AND QUANTITATIVE MAGNETIC RESONANCE IMAGING WITH BLIP UP-DOWN ACQUISITION OF SPIN- AND GRADIENT-ECHOES

      
Application Number 18552973
Status Pending
Filing Date 2022-03-28
First Publication Date 2024-06-06
Owner The General Hospital Corporation (USA)
Inventor
  • Bilgic, Berkin
  • Zhang, Zijing
  • Liao, Congyu
  • Cho, Jaejin
  • Manhard, Mary Kate

Abstract

Magnetic resonance imaging (“MRI”) using a spin- and gradient-echo (“SAGE”) pulse sequence with blip up-down acquisition (“BUDA”) encoding enables distortion-free, high-resolution diffusion-weighted imaging and/or quantitative parameter mapping. Phase-encoding polarities are alternated across shots during a multi-shot acquisition. In each shot, multi-contrast data are acquired at echo times associated with a gradient echo, a mixed gradient-and-spin echo, and a spin echo. High in-plane resolution and distortion-free quantitative parameter maps can be generated, such as T2 maps. T2* maps, paramagnetic susceptibility maps, and diamagnetic susceptibility maps. Diffusion-weighted data can be acquired using diffusion encoding gradients and BUDA encoding, where multi-contrast data are acquired in the b=0 acquisition. Diffusion parameter maps can be generated from the b=0 and diffusion-weighted data.

IPC Classes  ?

  • G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
  • G01R 33/50 - NMR imaging systems based on the determination of relaxation times
  • G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
  • G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences

27.

COMPOUNDS FOR BRAIN IMAGING

      
Application Number 18279162
Status Pending
Filing Date 2022-03-11
First Publication Date 2024-05-30
Owner The General Hospital Corporation (USA)
Inventor
  • Wang, Changning
  • Xu, Yulong
  • Zhang, Can
  • Tanzi, Rudolph E.

Abstract

The present application provides radiolabeled tetrahydrocarbazole compounds that can be used as positron emission tomography imaging probes. Pharmaceutical compositions and methods of using these compounds for diagnosis and monitoring treatment of neurodegenerative diseases (such as Alzheimer's disease) are also provided.

IPC Classes  ?

  • C07D 209/88 - Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
  • A61K 51/04 - Organic compounds
  • C07B 59/00 - Introduction of isotopes of elements into organic compounds

28.

ANTI-ARA H 2 ANTIBODIES AND USES THEREOF

      
Application Number 18285065
Status Pending
Filing Date 2022-03-31
First Publication Date 2024-05-30
Owner The General Hospital Corporation (USA)
Inventor Patil, Sarita U.

Abstract

The invention provides anti-Ara h 2 antibodies (e.g., an anti-Ara h 2 neutralizing antibody) and methods of using the same, e.g., for treating and/or preventing peanut allergy or sensitivity. Also provided herein are anti-Ara h 2 antibodies and methods of using the same, e.g., for diagnostics and methods of monitoring peanut oral immunotherapy. Also provided are combinations of anti-Ara h 2 antibodies for use in determining a treatment response of an individual with a peanut allergy to peanut exposure. Also provided are methods for assessing a treatment response of an individual with a peanut allergy to peanut exposure.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • C07K 16/16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from plants

29.

Biosensors in Human Gut Organoids

      
Application Number 18432695
Status Pending
Filing Date 2024-02-05
First Publication Date 2024-05-30
Owner
  • The General Hospital Corporation (USA)
  • Massachusetts Institute of Technology (USA)
Inventor
  • Fasano, Alessio
  • Lu, Timothy K.
  • Senger, Stefania
  • Inda, Maria Eugenia

Abstract

Ex vivo monolayer models of human interstinal epithelia that express sensors, and methods of use thereof for evaluation of the effects of test compounds on the human gut.

IPC Classes  ?

  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

30.

METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS

      
Application Number 18550914
Status Pending
Filing Date 2022-03-17
First Publication Date 2024-05-30
Owner
  • MEMORIAL SLOAN-KETTERING CANCER CENTER (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (USA)
  • SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (USA)
Inventor
  • Spriggs, David
  • Yeku, Oladapo

Abstract

The present technology provides methods for treating gynecologic cancers using combination therapy with an anti-MUC16×CD3 multispecific (e.g., bispecific) immunoglobulin-related composition that specifically binds to the C-terminal 114 amino acid residues of mature MUC16 (e.g., MUC16C114) and T cells, and a VEGF inhibitor. Kits for use in practicing the methods are also provided.

IPC Classes  ?

  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 35/00 - Antineoplastic agents
  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

31.

INJECTABLE FILLER FROM AUTOLOGOUS DERMIS WITHOUT DONOR SCARRING

      
Application Number 18551349
Status Pending
Filing Date 2022-03-22
First Publication Date 2024-05-30
Owner The General Hospital Corporation (USA)
Inventor
  • Wang, Ying
  • Anderson, R. Rox
  • Farinelli, William
  • Tam, Joshua

Abstract

A system and method for providing an autologous bio-filler to a patient is provided. The method includes harvesting dermal columns from a harvesting site and mincing the dermal columns into microsegments, where the microsegments form the autologous bio-filler. The method also includes injecting the autologous bio-filler into a recipient site of the patient.

IPC Classes  ?

  • A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61B 17/32 - Surgical cutting instruments
  • A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • A61L 27/50 - Materials characterised by their function or physical properties
  • A61Q 19/08 - Anti-ageing preparations
  • A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets
  • A61B 17/322 - Skin grafting apparatus

32.

GLYCOENGINEERING

      
Application Number 18142129
Status Pending
Filing Date 2023-05-02
First Publication Date 2024-05-30
Owner The General Hospital Corporation (USA)
Inventor
  • Anthony, Robert M.
  • Kitaoka, Maya

Abstract

This disclosure relates to glycoengineering, and methods of utilizing glycoengineering for various therapeutic purposes.

IPC Classes  ?

  • C12N 9/10 - Transferases (2.)
  • A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

33.

SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES

      
Application Number 18263432
Status Pending
Filing Date 2022-01-31
First Publication Date 2024-05-30
Owner
  • Janssen Biotech, Inc. (USA)
  • The Broad Institute, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Bacani, Genesis M.
  • Chai, Wenying
  • Chung, De Michael
  • Goldberg, Steven D.
  • Hirst, Gavin
  • Kaushik, Virendar
  • Mercado-Marin, Eduardo V.
  • Raymond, Donald
  • Seierstad, Mark
  • Smith, Russel C.
  • Sundberg, Thomas
  • Tichenor, Mark S.
  • Venable, Jennifer D.
  • Wei, Jianmei
  • Xavier, Ramnik

Abstract

Small molecule inhibitors of salt inducible kinases (SIKs) are provided. In particular, compounds of formula (II) and compounds of formula (III), and tautomers, stereoisomers, pharmaceutically acceptable salts and solvates thereof are provided. Also provided are pharmaceutical compositions containing the compounds, methods of preparing the compounds, and methods of using the compounds for inhibiting SIKs, such as SIK1 and SIK2, and methods of treating diseases mediated by SIKs. Small molecule inhibitors of salt inducible kinases (SIKs) are provided. In particular, compounds of formula (II) and compounds of formula (III), and tautomers, stereoisomers, pharmaceutically acceptable salts and solvates thereof are provided. Also provided are pharmaceutical compositions containing the compounds, methods of preparing the compounds, and methods of using the compounds for inhibiting SIKs, such as SIK1 and SIK2, and methods of treating diseases mediated by SIKs.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

34.

Compositions and Methods for the Treatment of Conditions Associated with Nucleotide Repeat Expansion

      
Application Number 18282421
Status Pending
Filing Date 2022-03-16
First Publication Date 2024-05-30
Owner The General Hospital Corporation (USA)
Inventor
  • Lee, Jeannie T.
  • Lee, Hun-Goo

Abstract

Described herein are compositions and methods that can be used to contract nucleotide repeat expansion (e.g., CGG) in a gene (e.g., FMR1) in cells of subjects having a condition associated with nucleotide repeat expansion, e.g., subjects with Fragile X syndrome (FXS), FXTAS-Parkinsonism, myotonic dystrophy, and other repeat disorders, by treating the cells using an inactive Cas9 protein and a guide RNA that directs the Cas9 to the gene or by treating the cells using a reactivation cocktail comprising small molecules.

IPC Classes  ?

  • A61K 35/545 - Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/90 - Stable introduction of foreign DNA into chromosome

35.

GLUCOSE CONTROL SYSTEM WITH AUTOMATIC ADAPTATION OF GLUCOSE TARGET

      
Application Number 18223315
Status Pending
Filing Date 2023-07-18
First Publication Date 2024-05-23
Owner
  • Trustees of Boston University (USA)
  • The General Hospital Corporation (USA)
Inventor
  • El-Khatib, Firas H.
  • Damiano, Edward R.
  • Russell, Steven J.

Abstract

A glucose control system employs adaptation of a glucose target (set-point) control variable in controlling delivery of insulin to a subject to maintain euglycemia. The glucose target adapts based on trends in actual glucose level (e.g., measured blood glucose in the subject), and/or computed doses of a counter-regulatory agent such as glucagon. An adaptation region with upper and lower bounds for the glucose target may be imposed. Generally the disclosed techniques can provide for robust and safe glucose level control. Adaptation may be based on computed doses of a counter-regulatory agent whether or not such agent is actually delivered to the subject, and may be used for example to adjust operation in a bihormonal system during periods in which the counter-regulatory agent is not available for delivery.

IPC Classes  ?

  • A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value

36.

RECAPITULATING THE HEMATOPOIETIC NICHE TO RECONSTITUTE IMMUNITY

      
Application Number 18224444
Status Pending
Filing Date 2023-07-20
First Publication Date 2024-05-23
Owner
  • President and Fellows of Harvard College (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Shah, Nisarg J.
  • Shih, Ting-Yu
  • Mao, Angelo S.
  • Mooney, David J.
  • Scadden, David T.

Abstract

Disclosed are compositions and related methods of recapitulating bone marrow stroma using scaffold materials (e.g., a porous alginate hydrogel scaffold) containing one or more cellular differentiation factors, and one or more growth factors. Such methods and compositions promote the formation of an ectopic nodule or site that can improve transplanted cell engraftment and selectively drive the development of lymphocytes and the reconstitution of the adaptive immunity after hematopoietic stem cell transplant.

IPC Classes  ?

37.

METHODS OF IDENTIFYING AND TREATING A PERSON HAVING A PREDISPOSITION TO OR AFFLICTED WITH A CARDIOMETABOLIC DISEASE

      
Application Number 18240789
Status Pending
Filing Date 2023-08-31
First Publication Date 2024-05-23
Owner
  • The Brigham and Women's Hospital, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Ebert, Benjamin Levine
  • Jaiswal, Siddhartha
  • Kathiresan, Sekar

Abstract

The invention relates to method for identifying and selecting a subject with increased risk of developing a cardiometabolic disease and optionally, providing a personalized medicine method, which may involve sequencing at least part of a genome of one or more cells in a blood sample of the subject and identifying from said sequencing one or more mutations in one or more somatic mutations.

IPC Classes  ?

  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

38.

METHOD AND APPARATUS FOR SELECTIVE TREATMENT OF BIOLOGICAL TISSUE

      
Application Number 18519731
Status Pending
Filing Date 2023-11-27
First Publication Date 2024-05-23
Owner
  • The General Hospital Corporation (USA)
  • Blossom Innovations, LLC (USA)
Inventor
  • Anderson, Richard Rox
  • Manstein, Dieter
  • Chan, Henry Hin Lee
  • Zuo, Vincent

Abstract

An exemplary treatment system can be provided which can include a laser system configured to emit at least one laser beam, and an optical system configured to focus the laser beam(s) to a focal region at a selected distance from a surface of a tissue. The focal region can be configured to illuminate at least a portion of a target. The optical system can cause an irradiation energy transferred to the focal region of the laser beam(s) to (i) generate a plasma in a first region of the tissue adjacent to the target, and (ii) avoid a generation of a plasma in a second region of the tissue. The optical system has a numerical aperture that is in the range of about 0.5 to about 0.9. An exemplary method can also be provided to control such treatment system.

IPC Classes  ?

  • A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
  • A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body

39.

PROTEIN PROSTHESES FOR MITOCHONDRIAL DISEASES OR CONDITIONS

      
Application Number 18516366
Status Pending
Filing Date 2023-11-21
First Publication Date 2024-05-16
Owner The General Hospital Corporation (USA)
Inventor
  • Mootha, Vamsi
  • Titov, Denis
  • Cracan, Valentin
  • Grabarek, Zenon

Abstract

The invention encompasses water-forming NADH and NADPH oxidases and the use of these enzymes to treat mammalian diseases or conditions associated with an elevated NADH/NAD+ ratio or NADPH/NADP+ ratio. Such pathologies include disorders caused by one or more defects in the mitochondrial respiratory chain, glucose metabolism disorders, cancers associated with reductive stress, and aging. The invention also provides a research tool for investigating the effect of exogenous water-forming NADH or NADPH oxidases on the metabolism of a mammalian cell, such as a human cell, and for elucidating the role of respiratory chain proteins in mitochondrial disorders.

IPC Classes  ?

  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K 14/335 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

40.

METHOD FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS (PBC) USING NOVEL AUTOANTIGENS

      
Application Number 18522114
Status Pending
Filing Date 2023-11-28
First Publication Date 2024-05-16
Owner
  • AMBERGEN, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Lim, Mark J.
  • Ostendorff, Heather P.
  • Rothschild, Kenneth J.
  • Bloch, Donald B.

Abstract

Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals.

IPC Classes  ?

  • G01N 33/564 - Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

41.

SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES

      
Application Number 18263384
Status Pending
Filing Date 2022-01-31
First Publication Date 2024-05-16
Owner
  • Janssen Biotech, Inc. (USA)
  • The Broad Institute, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Bacani, Genesis M.
  • Chai, Wenying
  • Chung, De Michael
  • Goldberg, Steven D.
  • Hirst, Gavin
  • Kaushik, Virnedar
  • Mercado-Marin, Eduardo V.
  • Raymond, Donald
  • Seierstad, Mark
  • Smith, Russel C.
  • Sundberg, Thomas
  • Tichenor, Mark S.
  • Venable, Jennifer D.
  • Wei, Jianmei
  • Xavier, Ramnik
  • Steffens, Helena C.

Abstract

Small molecule inhibitors of salt inducible kinases (SIKs) are provided. In particular, compounds of formula (I), and tautomers, stereoisomers, pharmaceutically acceptable salts and solvates thereof are provided. Also provided are pharmaceutical compositions containing the compounds, methods of preparing the compounds, and methods of using the compounds for inhibiting SIKs, such as SIK1 and SIK2, and methods of treating diseases mediated by SIKs. Small molecule inhibitors of salt inducible kinases (SIKs) are provided. In particular, compounds of formula (I), and tautomers, stereoisomers, pharmaceutically acceptable salts and solvates thereof are provided. Also provided are pharmaceutical compositions containing the compounds, methods of preparing the compounds, and methods of using the compounds for inhibiting SIKs, such as SIK1 and SIK2, and methods of treating diseases mediated by SIKs.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • C07D 487/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

42.

Humanized mAb107

      
Application Number 18283927
Status Pending
Filing Date 2022-03-25
First Publication Date 2024-05-16
Owner The General Hospital Corporation (USA)
Inventor Arnaout, M. Amin

Abstract

Described herein are humanized antibodies that bind to Leukocyte integrin CD11b/CD18 (CD11b, αMβ2, CR3) with enhanced affinity, and methods of use thereof.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

43.

METHODS OF PREPARING NUCLEIC ACIDS FOR SEQUENCING

      
Application Number 18481021
Status Pending
Filing Date 2023-10-04
First Publication Date 2024-05-16
Owner
  • The Geneal Hospital Corporation (USA)
  • ARCHERDX, LLC (USA)
Inventor
  • Iafrate, Anthony John
  • Le, Long Phi
  • Zheng, Zongli
  • Myers, Jason
  • Stahl, Joshua

Abstract

Aspects of the technology disclosed herein relate to methods for preparing and analyzing nucleic acids. In some embodiments, methods for preparing nucleic acids for sequence analysis (e.g., using next-generation sequencing) are provided herein.

IPC Classes  ?

  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
  • C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection

44.

RESOLVING ABSOLUTE DEPTH IN CIRCULAR-RANGING OPTICAL COHERENCE TOMOGRAPHY

      
Application Number 17755452
Status Pending
Filing Date 2020-10-30
First Publication Date 2024-05-16
Owner The General Hospital Corporation (USA)
Inventor
  • Vakoc, Benjamin
  • Lippok, Norman

Abstract

An apparatus, including: an electromagnetic radiation source producing radiation for illuminating a sample located at an optical path depth, the electromagnetic radiation source providing the radiation to the sample to facilitate determining the optical path depth within the sample: an interferometer including: a reference arm a first portion of the radiation is delivered to, a sample arm to which a second portion of the radiation is delivered, a first optical subsystem coupled to the sample arm to interrogate the sample with the radiation delivered to the sample arm and to collect backscattered radiation from the sample, and a second optical subsystem coupled to the reference arm and the first optical subsystem to generate interference fringes between the collected backscattered radiation and the radiation delivered to the reference arm; and a data collection and processing system configured to compute the optical path depth of the sample from the received interference fringes.

IPC Classes  ?

  • G01N 21/45 - Refractivity; Phase-affecting properties, e.g. optical path length using Schlieren methods

45.

PERSONALIZED REDIRECTION AND REPROGRAMMING OF T CELLS FOR PRECISE TARGETING OF TUMORS

      
Application Number 18279848
Status Pending
Filing Date 2022-03-01
First Publication Date 2024-05-09
Owner
  • Dana-Farber Cancer Institute, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Schwartz, Marc
  • Hacohen, Nir

Abstract

The disclosure provides methods of reprogramming polyclonal T cells to maintain long-term persistence. The disclosure further provides methods of treatment, such as adoptive T cell transfer therapies, that harness Tscms for development of tumor-reactive T cells. In some embodiments, the disclosure provides methods and compositions for positive modulation of the Tscm-producing phenotype, e.g., positive modulation of TCF7 expression. Positive modulation of TCF7 expression allows for maintenance of an increased T number of stem-like T cells capable of both self-renewal and generation of differentiated, cytolytic progeny.

IPC Classes  ?

  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/86 - Viral vectors

46.

HDAC6 Inhibitors and Imaging Agents

      
Application Number 18390906
Status Pending
Filing Date 2023-12-20
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Hooker, Jacob
  • Wang, Changning
  • Strebl-Bantillo, Martin Georg
  • Rokka, Johanna Kaarina

Abstract

Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided.

IPC Classes  ?

  • A61K 51/04 - Organic compounds
  • C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings

47.

METHOD AND APPARATUS FOR TIGHTENING SKIN AND OTHER TISSUES

      
Application Number 18531327
Status Pending
Filing Date 2023-12-06
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Mccormack, Michael
  • Redmond, Robert
  • Austen, Jr., William Gerald

Abstract

A system and method for treating a tissue is provided. The treatment causes a tightening or lifting of tissue. The method includes delivering a photochemical agent through a depth of the tissue to distribute the photochemical agent adjacent proteins within the tissue and irradiating the tissue with an electromagnetic irradiation at a wavelength that activates the photochemical agent, causing a protein response that brings fibers of the tissue closer together in order to one of reduce tissue laxity and tighten the tissue. A kit is provided to facilitate the method.

IPC Classes  ?

  • A61N 5/06 - Radiation therapy using light
  • A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser

48.

Astrocyte Interleukin-3 Reprograms Microglia and Limits Alzheimer`s Disease

      
Application Number 18274677
Status Pending
Filing Date 2022-02-04
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Mcalpine, Cameron
  • Swirski, Filip K.
  • Tanzi, Rudolph E.

Abstract

Described herein are compositions and methods targeting IL-3 signaling for reducing Alzheimer's disease (AD)-related pathology.

IPC Classes  ?

  • A61K 38/20 - Interleukins
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

49.

Highly Sensitive EGFRvIII Detection

      
Application Number 18503936
Status Pending
Filing Date 2023-11-07
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Balaj, Leonora
  • Carter, Bob S.
  • Batool, Syeda Maheen

Abstract

Provided herein are methods for the detection of EGFRvIII mutation in patient samples, e.g., in tumor tissue, cerebrospinal fluid, and plasma samples, using an optimized ddPCR assay. This methods can be used, e.g., for diagnosis, monitoring tumor progression, and assessing response to therapy.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • C12Q 1/6851 - Quantitative amplification

50.

ACTIVE QUADRATURE DEMODULATION FOR SUBSAMPLED/CIRCULAR RANGING OPTICAL COHERENCE TOMOGRAPHY

      
Application Number 18505342
Status Pending
Filing Date 2023-11-09
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Vakoc, Benjamin J.
  • Lippok, Norman

Abstract

A method including: scanning a sample over a period of time using an electro-magnetic radiation source, the period of time including a first time period and a second time period, a sample portion of the electro-magnetic radiation source being directed to the sample in a sample arm of an optical interferometric system, and a reference portion of the electro-magnetic radiation source being directed to a reference arm of the optical interferometric system; applying, using a phase modulator, a phase shift comprising a first phase shift and a second phase shift to at least one of the reference portion or the sample portion of the electro-magnetic radiation source, the first phase shift being applied during the first time period and the second phase shift being applied during the second time period, the second phase shift having a difference of 90 degrees from the first phase shift.

IPC Classes  ?

  • G01B 9/02001 - Interferometers characterised by controlling or generating intrinsic radiation properties
  • G01B 9/02091 - Tomographic interferometers, e.g. based on optical coherence

51.

Engineered CRISPR-Cas9 nucleases with Altered PAM Specificity

      
Application Number 18507709
Status Pending
Filing Date 2023-11-13
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Joung, J. Keith
  • Kleinstiver, Benjamin

Abstract

Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.

IPC Classes  ?

  • C12N 9/22 - Ribonucleases
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/90 - Stable introduction of foreign DNA into chromosome

52.

SYSTEM AND METHOD FOR DIAGNOSING CELIAC DISEASE

      
Application Number 18548951
Status Pending
Filing Date 2022-03-07
First Publication Date 2024-05-09
Owner The General Hospital Corporation (USA)
Inventor
  • Tearney, Guillermo J.
  • Girish, Gududappanavar Nagarajappa
  • Otuya, David Odeke

Abstract

A method for identifying an intestinal disorder in a subject, including: obtaining an image of a small intestinal region of the subject; identifying a villus structure in the image; measuring at least one feature based on the identified villus structure to obtain a metric; and identifying an intestinal disorder based on the metric.

IPC Classes  ?

53.

CAL-T CONSTRUCTS AND USES THEREOF

      
Application Number 17769495
Status Pending
Filing Date 2020-10-16
First Publication Date 2024-05-02
Owner
  • TRUSTEES OF BOSTON UNIVERSITY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Pakyari, Mohammadreza
  • Wong, Wilson
  • Okuma, Atsushi
  • Cetrulo, Curtis

Abstract

The technology described herein is directed to compositions comprising components of multi-component CALs or CARs, e.g., a TCR recognition domain; and one or both of: (a) an intracellular signaling domain; and (b) a first-type protein interaction domain. Further provided herein are methods for treating or preventing an autoimmune disease, a transplant rejection, or graft versus host disease.

IPC Classes  ?

  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61P 35/00 - Antineoplastic agents
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

54.

FETAL ANEUPLOIDY DETECTION BY SEQUENCING

      
Application Number 18310098
Status Pending
Filing Date 2023-05-01
First Publication Date 2024-05-02
Owner
  • Verinata Health, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Stoughton, Roland
  • Kapur, Ravi
  • Cohen, Barb Ariel
  • Toner, Mehmet

Abstract

The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions.

IPC Classes  ?

  • C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

55.

SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY

      
Application Number 18324598
Status Pending
Filing Date 2023-05-26
First Publication Date 2024-05-02
Owner
  • The Children's Medical Center Corporation (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Ozcan, Umut
  • Mazitschek, Ralph
  • Guan, Dongxian

Abstract

Formulations of HDAC6 inhibitors passing through the blood brain barrier in hypothalamus and inhibiting HDAC6 in the arctuate AgRP neurons in the hypothalamus, are effective to cause weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin-resistant individuals.

IPC Classes  ?

  • A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
  • A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61P 3/04 - Anorexiants; Antiobesity agents

56.

LIGHT-BASED SYSTEM AND METHOD FOR SHAPING AND TREATING HAIR

      
Application Number 18409614
Status Pending
Filing Date 2024-01-10
First Publication Date 2024-05-02
Owner The General Hospital Corporation (USA)
Inventor
  • Austen, William G.
  • Redmond, Robert
  • Mccormack, Michael

Abstract

System and methods for treating and shaping a keratin fiber are provided. A light-based system includes an activation system configured with one or more light source. The light source is configured to apply electromagnetic radiation at a target region including the keratin fiber. The light-based system applies the electromagnetic radiation to the target region to effectuate photocrosslinking with the assistance of a photosensitizer on the keratin fiber and transition the keratin fiber from a first physical state to a second physical state.

IPC Classes  ?

  • A61N 5/06 - Radiation therapy using light
  • A45D 1/04 - Curling-tongs, i.e. tongs for use when hot; Curling-irons, i.e. irons for use when hot; Accessories therefor with means for internal heating, e.g. by liquid fuel by electricity
  • A45D 2/00 - Hair-curling or hair-waving appliances

57.

Methods for Treating Autism Spectrum Disorder

      
Application Number 18274435
Status Pending
Filing Date 2022-02-02
First Publication Date 2024-04-25
Owner The General Hospital Corporation (USA)
Inventor Joshi, Gagan

Abstract

Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with autism spectrum disorder (ASD).

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • A61K 31/13 - Amines, e.g. amantadine
  • A61P 25/00 - Drugs for disorders of the nervous system

58.

PHOTO-ECMO APPARATUS, SYSTEMS, AND METHODS

      
Application Number 18547969
Status Pending
Filing Date 2022-02-25
First Publication Date 2024-04-25
Owner The General Hospital Corporation (USA)
Inventor
  • Anderson, Richard Rox
  • Zapol, Warren
  • Fischbach, Anna
  • Farinelli, William A
  • Korupolu, Sandeep

Abstract

An apparatus for removing CO from blood, the apparatus including: a housing configured to house blood obtained from a body of a subject within an interior of the housing; a plurality of gas-permeable tubules disposed within the interior of the housing; an optical intrusion coupled to the housing and configured to project into the housing, the optical intrusion configured to transmit light into the interior of the housing; and a light source optically coupled to the optical intrusion, the light source being configured to emit light which is coupled via the optical intrusion into the interior of the housing such that the emitted light interacts with the blood from the body of the subject.

IPC Classes  ?

  • A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
  • A61M 1/16 - Dialysis systems; Artificial kidneys; Blood oxygenators with membranes

59.

Digital Analysis of Circulating Tumor Cells in Blood Samples

      
Application Number 18396156
Status Pending
Filing Date 2023-12-26
First Publication Date 2024-04-25
Owner The General Hospital Corporation (USA)
Inventor
  • Haber, Daniel A.
  • Kapur, Ravi
  • Toner, Mehmet
  • Maheswaran, Shyamala
  • Hong, Xin
  • Miyamoto, David Tomoaki
  • Todorova, Tanya
  • Javaid, Sarah

Abstract

This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • C12Q 1/686 - Polymerase chain reaction [PCR]

60.

METHODS AND SYSTEMS FOR SAFE INJECTION OF DERMAL FILLER PROCEDURES

      
Application Number 18547917
Status Pending
Filing Date 2022-02-25
First Publication Date 2024-04-25
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wanner, Molly
  • Farinelli, William
  • Anderson, Richard Rox
  • Gardecki, Joseph A.
  • Beatty, Matthew J.
  • Tearney, Guillermo J.

Abstract

An injection apparatus, including: a needle configured to be inserted into a tissue; a light source to deliver light to the tissue to generate reflected light; a detector to detect the reflected light from the tissue; a processor coupled to the detector and configured to: analyze the reflected light from the tissue to identify a tissue type associated with the reflected light, and provide an output to a user based on the identified tissue type.

IPC Classes  ?

  • A61M 5/31 - Syringes - Details
  • A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
  • A61M 5/34 - Constructions for connecting the needle

61.

LUNG BIOREACTOR

      
Application Number 18391115
Status Pending
Filing Date 2023-12-20
First Publication Date 2024-04-18
Owner The General Hospital Corporation (USA)
Inventor Ott, Harald C.

Abstract

Presented is an airway organ bioreactor apparatus, and methods of use thereof, as well as bioartificial airway organs produced using the methods, and methods of treating subjects using the bioartificial airway organs. The bioreactor comprises: an organ chamber: an ingres line connecting the organ chamber and a reservoir system and comprising an arterial line, a venous line and a tracheal line; an egress line connecting the chamber and the reservoir system, pumps in ingress and egress lines; a controller to control fluid exchange; a chamber pressure sensor connected to the organ chamber.

IPC Classes  ?

  • C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
  • A01N 1/02 - Preservation of living parts
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 35/36 - Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
  • A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
  • A61K 35/44 - Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
  • C12M 1/00 - Apparatus for enzymology or microbiology
  • C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
  • C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
  • C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors

62.

HIGH-THROUGHPUT ASSESSMENT OF EXOGENOUS POLYNUCLEOTIDE- OR POLYPEPTIDE-MEDIATED TRANSCRIPTOME PERTURBATIONS

      
Application Number 18547258
Status Pending
Filing Date 2022-02-22
First Publication Date 2024-04-18
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Al'Khafaji, Aziz
  • Keer, Frances
  • Blainey, Paul
  • Hacohen, Nir

Abstract

The present disclosure relates to methods and compositions for enhanced assessment of exogenous polynucleotide and/or polypeptide-mediated transcriptional perturbations at high throughput and single cell/droplet levels of resolution. In embodiments, nucleic acid fusions of exogenous polynucleotide(s) and associated target transcript(s) are produced within individually sequestered or discretely identifiable cells/lysates and analyzed for exogenous polynucleotide mediated perturbations across a vast population of droplets/cells within individual reactions. Kits for performance of the methods are also provided.

IPC Classes  ?

63.

PANELS AND METHODS FOR TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA

      
Application Number 18468384
Status Pending
Filing Date 2023-09-15
First Publication Date 2024-04-11
Owner
  • The Broad Institute, Inc. (USA)
  • Dana-Farber Cancer Institute, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Chapuy, Bjoern
  • Stewart, Donald
  • Wood, Tim
  • Shipp, Margaret
  • Getz, Gad
  • Murakami, Mark
  • Lawton, Lee
  • Dunford, Andrew
  • Wienand, Kirsty

Abstract

The invention provides a molecular classifier and a targeted sequencing assay for use in characterization and treatment of diffuse large B-cell lymphoma.

IPC Classes  ?

  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • C12Q 1/6869 - Methods for sequencing
  • G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
  • G16B 40/20 - Supervised data analysis

64.

SYSTEM AND METHOD FOR NON-INVASIVE, INTRACRANIAL BRAIN MOTION MONITORING

      
Application Number 18538583
Status Pending
Filing Date 2023-12-13
First Publication Date 2024-04-11
Owner The General Hospital Corporation (USA)
Inventor
  • Zhang, Quan
  • Strangman, Gary

Abstract

A system and a method is provided for assessing motion of a biological tissue of a subject including one or more superficial biological layers and a targeted biological layer. A perturbation unit provide an optical perturbation to the one or more superficial biological layers. An optical signal generator transmits optical signals at one or more near-infrared wavelengths. An optical signal receiver acquires a set of optical signal data preceding, during, or following the optical perturbation at a first acquisition time relative to the optical perturbation. A signal processor determines, using the set of optical signal data, a set of optical characteristics and separates, using the set of optical characteristics, a target optical signal. The signal processor generates a report indicative of a movement of the targeted biological tissue within the subject. The movement of the targeted biological layer is calculated using the target optical signal.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters

65.

METHOD AND APPARATUS FOR TISSUE GRAFTING AND COPYING

      
Application Number 18483848
Status Pending
Filing Date 2023-10-10
First Publication Date 2024-04-11
Owner The General Hospital Corporation (USA)
Inventor
  • Anderson, Richard Rox
  • Farinelli, William A.
  • Franco, Walfre
  • Tam, Joshua
  • Sakamoto, Fernanda H.
  • Doukas, Apostolos G.
  • Purschke, Martin
  • Yao, Min

Abstract

Exemplary embodiments of apparatus and method for obtaining one or more portions of biological tissue (“micrografts”) to form grafts are provided. For example, a hollow tube can be inserted into tissue at a donor site, and a pin provided within the tube can facilitate controlled removal of the micrograft from the tube. Micrografts can be harvested and directly implanted into an overlying biocompatible matrix through coordinated motion of the tube and pin. A needle can be provided around the tube to facilitate a direct implantation of a micrograft into a remote recipient site or matrix. The exemplary apparatus can include a plurality of such tubes and pins for simultaneous harvesting and/or implanting of a plurality of micrografts. The harvested micrografts can have a small dimension, e.g., less than about 1 mm, which can promote healing of the donor site and/or viability of the harvested tissue.

IPC Classes  ?

66.

INTERPRETATION OF INTRAOPERATIVE SENSOR DATA USING CONCEPT GRAPH NEURAL NETWORKS

      
Application Number 18550367
Status Pending
Filing Date 2022-03-28
First Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Meireles, Ozanan R.
  • Ban, Yutong
  • Hashimoto, Daniel A.
  • Rosman, Guy
  • Ward, Thomas
  • Rus, Daniela

Abstract

Systems and methods are provided for generating a statistical parameter representing a state of a surgical procedure from sensor data. Sensor data representing a time period. is received from a sensor. Numerical features representing the time period are generated from the sensor data. Each of a plurality of long short term memory units are updated according to the plurality of numerical features via a message passing process. The long short term memory units are connected to form a graph, with a first set of the long short term memory units representing a plurality of nodes of the graph and a second set of the long short term memory units representing a plurality of hyperedges of the graph. A statistical parameter representing a state of the surgical procedure for the time period is derived from an output of one of the long short term memory units and provided to a user.

IPC Classes  ?

  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
  • G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

67.

METHODS FOR INHIBITING RAS

      
Application Number 18479500
Status Pending
Filing Date 2023-10-02
First Publication Date 2024-04-04
Owner
  • The General Hospital Corporation (USA)
  • Revolution Medicines, Inc. (USA)
Inventor
  • Corcoran, Ryan B.
  • Nichols, Robert J.

Abstract

The disclosure features methods for inhibiting RAS proteins, e.g., RAS proteins that have acquired resistance to one or more RAS inhibitors. The disclosure also methods for the treatment of cancer.

IPC Classes  ?

  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 35/00 - Antineoplastic agents

68.

Minimally Invasive Devices and Methods for Measuring Intestinal Potential Difference

      
Application Number 18263558
Status Pending
Filing Date 2022-01-31
First Publication Date 2024-04-04
Owner The General Hospital Corporation (USA)
Inventor
  • Tearney, Guillermo
  • Otuya, David Odeke
  • Farrokhi, Hamid
  • Shi, Serena Qinyun Z
  • Silva, Sarah Lynn
  • Dong, Jing

Abstract

A system for determining intestinal potential difference. The system includes a measurement probe including a measurement tube having a measurement lumen which houses a measurement electrode therein, a measurement fluid delivery system in fluid communication with the measurement lumen, the measurement fluid delivery system being configured to deliver an electrically-conductive fluid into the measurement lumen such that the electrically-conductive fluid is electrically coupled to the measurement electrode, and the measurement lumen including an outlet at a distal end thereof through which the electrically-conductive fluid exits the measurement lumen and contacts an intestinal tissue of a subject to provide electrical coupling between the measurement electrode and the intestinal tissue; a controller coupled to the measurement electrode configured to measure a potential difference between tire measurement electrode and a reference electrode electrically coupled to the subject.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
  • A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
  • A61B 5/262 - Needle electrodes
  • A61B 5/265 - Bioelectric electrodes therefor characterised by the electrode materials containing silver or silver chloride
  • A61B 5/301 - Input circuits therefor providing electrical separation, e.g. by using isolating transformers or optocouplers

69.

MODULATION OF A PATHOGENIC PHENOTYPE IN TH1 CELLS

      
Application Number 18273579
Status Pending
Filing Date 2022-01-21
First Publication Date 2024-04-04
Owner
  • The Brigham and Women's Hospital, Inc. (USA)
  • The Broad Institute, Inc. (USA)
  • The General Hospital Corporation (USA)
  • The Regents of the University of California (USA)
Inventor
  • Kuchroo, Vijay K.
  • Xavier, Ramnik
  • Pawlak, Mathias
  • Detomaso, David
  • Yosef, Nir

Abstract

The subject matter disclosed herein is generally directed to pathogenic Th1 cells whose phenotype is dependent on IL-23R signaling. Th1 cell specific therapeutic targets and gene programs are disclosed herein. In particular, inhibition of CD160 reduces Th1 cell pathogenicity.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61P 37/02 - Immunomodulators
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • C12N 9/22 - Ribonucleases

70.

FC-ENHANCED ANTIBODIES FOR PREVENTION AND TREATMENT OF EBOLA VIRUS INFECTION

      
Application Number 18274641
Status Pending
Filing Date 2022-02-01
First Publication Date 2024-04-04
Owner The General Hospital Corporation (USA)
Inventor
  • Alter, Galit
  • Lu, Richard

Abstract

Described herein are Fe-enhanced antibodies and methods of use thereof. Also described are Fe-enhanced antibodies to treat Ebola virus infection.

IPC Classes  ?

  • C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
  • A61P 31/14 - Antivirals for RNA viruses

71.

GASTRORETENTIVE ARTICLES FOR ALCOHOL SENSING

      
Application Number 18541818
Status Pending
Filing Date 2023-12-15
First Publication Date 2024-04-04
Owner
  • Massachusetts Institute of Technology (USA)
  • The Brigham and Women's Hospital, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Langer, Robert S.
  • Traverso, Carlo Giovanni
  • Verma, Malvika
  • Eweje, Feyisope
  • Steiger, Christoph Winfried Johannes
  • Li, Junwei
  • Phan, Nhi
  • Huang, Hen-Wei
  • Chu, Jacqueline
  • Salama, John Ashraf Fou

Abstract

Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).

IPC Classes  ?

  • A61B 5/07 - Endoradiosondes
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

72.

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES

      
Application Number 18273395
Status Pending
Filing Date 2022-01-21
First Publication Date 2024-03-28
Owner The General Hospital Corporation (USA)
Inventor Faustman, Denise L.

Abstract

The disclosure features antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the downstream signaling of TNFR superfamily members. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, infectious diseases, autoimmune disorders, obesity, type 2 diabetes, neurological disorders, and osteoporosis.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

73.

METHODS AND COMPOSITION FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER

      
Application Number 18270611
Status Pending
Filing Date 2021-12-30
First Publication Date 2024-03-28
Owner The General Hospital Corporation (USA)
Inventor Kong, Xue-Jun

Abstract

Disclosed herein are methods and compositions useful for the treatment of Autism Spectrum Disorder (ASD). The methods and compositions include combination therapy with probiotics and oxytocin (OXT), resulting in a therapeutic synergy that exerts beneficial effects on ASD symptoms. The methods and compositions provide improvements in several measurable parameters including but not limited to: measured clinical index for ASD core symptoms, gut microbiome profile, and levels of OXT and inflammatory markers in the blood.

IPC Classes  ?

  • A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
  • A61K 38/095 - Oxytocins; Vasopressins; Related peptides
  • A61P 25/00 - Drugs for disorders of the nervous system

74.

T CELL-DIRECTED ANTI-CANCER VACCINES AGAINST COMMENSAL VIRUSES FOR TREATING MUCOSAL CARCINOMAS

      
Application Number 18273466
Status Pending
Filing Date 2022-01-21
First Publication Date 2024-03-28
Owner The General Hospital Corporation (USA)
Inventor Demehri, Shadmehr

Abstract

Immune-based approaches to treat and reduce the risk of cancer of mucosal tissues by boosting T cell immunity against commensal HPVs.

IPC Classes  ?

  • A61K 39/12 - Viral antigens
  • A61P 35/00 - Antineoplastic agents
  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

75.

COMPOUNDS FOR TAU PROTEIN DEGRADATION

      
Application Number 18200950
Status Pending
Filing Date 2023-05-23
First Publication Date 2024-03-21
Owner
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITAL (USA)
Inventor
  • Gray, Nathanael S.
  • Haggarty, Stephen J.
  • Cai, Quan
  • Zhang, Tinghu
  • Telo Baptista Lima Da Silva, Maria Catarina
  • Ferguson, Fleur M.

Abstract

Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein, a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasomal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

IPC Classes  ?

  • A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 38/05 - Dipeptides
  • A61K 51/04 - Organic compounds
  • C07D 471/04 - Ortho-condensed systems
  • C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
  • G01N 33/534 - Production of labelled immunochemicals with radioactive label
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

76.

GHRH OR ANALOGUES THEREOF FOR USE IN TREATMENT OF HEPATIC DISEASE

      
Application Number 18351169
Status Pending
Filing Date 2023-07-12
First Publication Date 2024-03-21
Owner The General Hospital Corporation (USA)
Inventor Grinspoon, Steven K.

Abstract

The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.

IPC Classes  ?

  • A61K 38/25 - Growth hormone-releasing factor [GH-RF] (Somatoliberin)
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

77.

Image-seq: A New Technology for Spatially-Resolved Single-Cell RNA Sequencing

      
Application Number 18363298
Status Pending
Filing Date 2023-08-01
First Publication Date 2024-03-21
Owner The General Hospital Corporation (USA)
Inventor
  • Haase, Christa
  • Richter, Dmitry
  • Lin, Charles

Abstract

A system and method for image-guided cell isolation from a region of interest of a subject is disclosed. The system and method include imaging the subject using optical microscopy to identify the region of interest in a target anatomy, inserting a micropipette into the region of interest under guidance of the optical microscopy, and aspirating at least one cell of a target population of cells in the region of interest under guidance of the optical microscopy. The method further includes analyzing the at least one cell aspirated from the region of interest.

IPC Classes  ?

  • C12Q 1/6869 - Methods for sequencing
  • A61B 10/02 - Instruments for taking cell samples or for biopsy
  • A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
  • A61B 90/20 - Surgical microscopes characterised by non-optical aspects

78.

Systemic Delivery of Polypeptides

      
Application Number 18325332
Status Pending
Filing Date 2023-05-30
First Publication Date 2024-03-21
Owner
  • President and Fellows of Harvard College (USA)
  • Massachusetts Institute of Technology (USA)
  • The Brigham and Women's Hospital, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Milanova, Denitsa M.
  • Church, George M.
  • Davidsohn, Noah
  • Schoellhammer, Carl
  • Langer, Robert S.
  • Mandinova, Anna I.
  • Traverso, Carlo Giovanni

Abstract

A method for the systemic delivery of a polypeptide within a subject is provided by creating genetically modified skin cells via topical introduction of a genetically engineered virus which delivers a nucleic acid encoding a therapeutic polypeptide for expression by the skin cells, wherein the expressed therapeutic polypeptide is secreted by the skin cells and is introduced into the circulatory system of the subject.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61N 7/00 - Ultrasound therapy
  • C12N 15/86 - Viral vectors

79.

COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION

      
Application Number 18351198
Status Pending
Filing Date 2023-07-12
First Publication Date 2024-03-14
Owner The General Hospital Corporation (USA)
Inventor
  • Ruvkun, Gary
  • Govindan, J. Amaranath
  • Jayamani, Elamparithi

Abstract

Provided herein are methods and compositions comprising a bacterium or a metabolite thereof for enhancing mitochondrial and/or peroxisomal function.

IPC Classes  ?

  • A61K 35/74 - Bacteria
  • A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
  • A23L 2/52 - Adding ingredients
  • A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C12N 1/20 - Bacteria; Culture media therefor
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)

80.

ANTI-BMP9 ANTIBODIES AND METHODS OF USE THEREOF

      
Application Number 18326335
Status Pending
Filing Date 2023-05-31
First Publication Date 2024-03-14
Owner
  • Pfizer Inc. (USA)
  • The Brigham and Women's Hospital, Inc. (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Yu, Paul B.
  • Apgar, James Reasoner
  • Benard, Susan Adam
  • Berasi, Stephen Peter
  • Huard, Christine
  • Kovalenko, Oleg Victorovich
  • Mosyak, Lidia
  • Tang, Xianchun
  • Tumelty, Kathleen Elisabeth
  • Troncone, Luca
  • Zhong, Ying

Abstract

Antibodies, and antigen-binding fragments thereof, that specifically bind to bone morphogenetic protein-9 (BMP9) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

IPC Classes  ?

  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • A61P 9/12 - Antihypertensives

81.

MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES

      
Application Number 18210992
Status Pending
Filing Date 2023-06-16
First Publication Date 2024-03-14
Owner The General Hospital Corporation (USA)
Inventor
  • Elmaleh, David R.
  • Tanzi, Rudolph E.
  • Shoup, Timothy M.
  • Gircluc, Ana

Abstract

Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

IPC Classes  ?

  • A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 311/22 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
  • C07D 311/24 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

82.

CD64 CHIMERIC RECEPTOR AND USES THEREOF

      
Application Number 18272168
Status Pending
Filing Date 2022-01-18
First Publication Date 2024-03-14
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • CONSIGLIO NAZIONALE DELLE RICERCHE (Italy)
Inventor
  • Ferrone, Soldano
  • Sconocchia, Giuseppe
  • Caratelli, Sara

Abstract

The present invention provides compositions and methods for treating cancer in a human. The invention includes a chimeric receptor which comprises an CD64 binding domain, a transmembrane domain, and a CD3zeta signaling domain.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 35/00 - Antineoplastic agents
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C07K 14/725 - T-cell receptors
  • C07K 14/735 - Fc receptors
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

83.

METHODS AND COMPOSITIONS FOR INCREASING THE CONCENTRATION OF CELL FREE DNA

      
Application Number 18273922
Status Pending
Filing Date 2022-01-25
First Publication Date 2024-03-14
Owner
  • The Broad Institute, Inc. (USA)
  • Massachusetts Institute of Technology (USA)
  • The General Hospital Corporation (USA)
Inventor
  • Adalsteinsson, Viktor A.
  • Tabrizi, Shervin
  • Bhatia, Sangeeta N.
  • Love, J. Christopher
  • Martin Alonso, Maria Carmen
  • Xiong, Kan

Abstract

This disclosure provides a method for substantially increasing the concentration of cfDNA in a patient. By injecting a patient with lipid and/or polymer nanoparticles, agents that bind cfDNA, or inhibit deoxyribonucleases prior to collection of a sample of cfDNA, e.g., by way of a liquid biopsy, major pathways for the degradation of cfDNA are temporarily blocked, permitting transient accumulation of cfDNA. This strategy has the potential to dramatically enhance the quality of detection achieved by downstream cfDNA e analytical applications, such as sequencing applications.

IPC Classes  ?

  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • A61K 9/51 - Nanocapsules
  • A61K 38/00 - Medicinal preparations containing peptides

84.

SYSTEM FOR MEASURING AND MONITORING BLOOD PRESSURE

      
Application Number 18388117
Status Pending
Filing Date 2023-11-08
First Publication Date 2024-03-14
Owner The General Hospital Corporation (USA)
Inventor
  • Zhang, Quan
  • Zhang, Yuanting

Abstract

A system and method for measuring and monitoring blood pressure is provided. The system includes a wearable device and a tonometry device coupled to the wearable device. The Tonometry device is configured to compress a superficial temporal artery (STA) of a user. A sensor pad is attached to the wearable device adjacent the tonometry device. A blood pressure sensor is integrated within the sensor pad for continuous, unobtrusive blood pressure monitoring.

IPC Classes  ?

  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/021 - Measuring pressure in heart or blood vessels
  • A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthaldynamometers
  • A61B 5/026 - Measuring blood flow
  • A61B 5/33 - Heart-related electrical modalities, e.g. electrocardiography [ECG] specially adapted for cooperation with other devices

85.

GENETIC VARIANTS ASSOCIATED WITH LOCAL FAT DEPOSITION TRAITS FOR THE TREATMENT OF HERITABLE METABOLIC DISORDERS

      
Application Number 18454465
Status Pending
Filing Date 2023-08-23
First Publication Date 2024-03-14
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Khera, Amit
  • Agrawal, Saaket
  • Klarqvist, Marcus
  • Batra, Puneet

Abstract

The subject matter disclosed herein is generally directed to genetic variants associated with local adiposity traits and metabolic disease. Embodiments disclosed herein provide genetic variants associated with local adiposity traits obtained by adjusting adiposity traits for BMI and height. Embodiments disclosed herein also provide genes linked to variants and associated with the local adiposity traits. The local adiposity traits are associated with metabolic disorders. In example embodiments, variants indicate risk for a metabolic disorder and can be used to determine treatment. In example embodiments, genes associated with local adiposity traits and/or variants can be targeted therapeutically. In example embodiments, a risk for a metabolic disorder can be determined by detecting one or more risk variants associated with a local adiposity trait.

IPC Classes  ?

  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

86.

SYSTEM AND METHOD FOR HIGH-RESOLUTION, HIGH-SPEED CAPSULE ENDOMICROSCOPY

      
Application Number 18510253
Status Pending
Filing Date 2023-11-15
First Publication Date 2024-03-14
Owner The General Hospital Corporation (USA)
Inventor
  • Tearney, Guillermo J.
  • Ryu, Jiheun

Abstract

A probe for performing endomicroscopy, including: a light source; a waveguide coupled to the light source; a diffraction grating, the waveguide directing light from the light source to the diffraction grating; and a lens having a first aspheric surface and a second biconic surface, diffracted light from the diffraction grating being directed into the aspheric surface of the lens and being emitted from the biconic surface of the lens towards a transparent cylindrical surface of the probe.

IPC Classes  ?

  • G02B 5/18 - Diffracting gratings
  • A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
  • A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G02B 21/00 - Microscopes
  • G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes

87.

Extracellular mRNA Markers of Muscular Dystrophies in Human Urine

      
Application Number 18517748
Status Pending
Filing Date 2023-11-22
First Publication Date 2024-03-14
Owner The General Hospital Corporation (USA)
Inventor
  • Wheeler, Thurman
  • Breakefield, Xandra O.
  • Balaj, Leonora

Abstract

Described herein are methods for diagnosing and monitoring subjects with diseases associated with aberrant splicing, based upon detecting properly spliced isoforms and mis-spliced isoforms in a urine sample from the subject.

IPC Classes  ?

  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • C12Q 1/6865 - Promoter-based amplification, e.g. nucleic acid sequence-based amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

88.

Methods for Detecting Site-Specific and Spurious Genomic Deamination Induced by Base Editing Technologies

      
Application Number 18339788
Status Pending
Filing Date 2023-06-22
First Publication Date 2024-03-07
Owner The General Hospital Corporation (USA)
Inventor
  • Joung, J. Keith
  • Angstman, James
  • Gehrke, Jason Michael

Abstract

Methodologies to detect off-target mutations induced by the deaminase activity of Base Editing technology.

IPC Classes  ?

  • C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
  • C12Q 1/6855 - Ligating adaptors
  • C12Q 1/6869 - Methods for sequencing

89.

METHODS FOR DETERMINING A NUCLEOTIDE SEQUENCE CONTIGUOUS TO A KNOWN TARGET NUCLEOTIDE SEQUENCE

      
Application Number 18459672
Status Pending
Filing Date 2023-09-01
First Publication Date 2024-03-07
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Iafrate, Anthony John
  • Le, Long Phi
  • Zheng, Zongli

Abstract

The technology described herein is directed to methods of determining oligonucleotide sequences, e.g. by enriching target sequences prior to sequencing the sequences.

IPC Classes  ?

  • C12Q 1/6855 - Ligating adaptors
  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
  • C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]

90.

AUTOMATED EVALUATION OF HUMAN EMBRYOS

      
Application Number 18507351
Status Pending
Filing Date 2023-11-13
First Publication Date 2024-03-07
Owner
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Shafiee, Hadi
  • Bormann, Charles
  • Kanakasabapathy, Manoj Kumar
  • Thirumalaraju, Prudhvi

Abstract

Systems and methods are provided for provided for automatic evaluation of a human embryo. An image of the embryo is obtained and provided to a neural network to generate a plurality of values representing the morphology of the embryo. The plurality of values representing the morphology of the embryo are evaluated at an expert system to provide an output class representing one of a current quality of the embryo, a future quality of the embryo, a likelihood that implantation of the embryo will be successful, and a likelihood that implantation of the embryo will result in a live birth.

IPC Classes  ?

91.

Polypeptide Integrin Antagonists

      
Application Number 18317017
Status Pending
Filing Date 2023-05-12
First Publication Date 2024-03-07
Owner The General Hospital Corporation (USA)
Inventor Arnaout, M. Amin

Abstract

The present application relates to polypeptides which are integrin antagonists. Methods of preparing the integrin antagonists and methods of treating diseases and disorders associated with abnormal levels and/or expression of one or more integrins are also provided.

IPC Classes  ?

  • C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 7/04 - Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

92.

DEVICES, SYSTEMS, AND METHODS FOR ADVANCING AND POSITIONING TETHERED CAPSULE MICROENDOSCOPES

      
Application Number 18472356
Status Pending
Filing Date 2023-09-22
First Publication Date 2024-03-07
Owner The General Hospital Corporation (USA)
Inventor
  • Tearney, Guillermo J.
  • Hyun, Chulho Daryl
  • Gardecki, Joseph A.

Abstract

In some embodiments, devices, systems, and methods for advancing and positioning tethered capsule microendoscopes are provided. In some embodiments, a device for capsule endomicroscopy is provided, comprising: a tether having a proximal end and distal end; an optical fiber disposed within the tether; a tube enclosing at least a portion of the tether, the tube having a proximal end and a distal end, a diameter of the tube being larger than the diameter of the tether; a housing coupled to the distal end of the tether and the distal end of the tube; and an optical element disposed within the housing, the optical element being optically coupled to the distal end of the optical fiber and configured to direct light received from the optical fiber toward a periphery of the housing.

IPC Classes  ?

  • A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
  • A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
  • A61B 1/005 - Flexible endoscopes
  • A61B 1/008 - Articulations
  • A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
  • A61B 1/273 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the upper alimentary canal, e.g. oesophagoscopes, gastroscopes
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

93.

CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING THE TUMOR MICROENVIRONMENT

      
Application Number 18477532
Status Pending
Filing Date 2023-09-28
First Publication Date 2024-03-07
Owner The General Hospital Corporation (USA)
Inventor
  • Maus, Marcela V.
  • Choi, Bryan

Abstract

The invention provides methods and compositions for use in treating cancer, which advantageously may be achieved by targeting of the tumor microenvironment.

IPC Classes  ?

  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61P 35/00 - Antineoplastic agents
  • C07K 14/725 - T-cell receptors
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

94.

Genome editing approaches to treat Spinal Muscular Atrophy

      
Application Number 18271190
Status Pending
Filing Date 2022-01-10
First Publication Date 2024-02-29
Owner The General Hospital Corporation (USA)
Inventor
  • Kleinstiver, Benjamin
  • Alves, Christiano Robles
  • Swoboda, Kathryn J.
  • Christie, Kathleen A.

Abstract

Described herein are methods and compositions for treating subjects with spinal muscular atrophy (SMA) using CRISPR editing of exon 7 and/or intron 7 of SMN2.

IPC Classes  ?

95.

VISCOELASTIC MECHANOPORATION SYSTEMS AND METHODS OF USE THEREOF

      
Application Number 18271826
Status Pending
Filing Date 2022-01-12
First Publication Date 2024-02-29
Owner The General Hospital Corporation (USA)
Inventor
  • Sevenler, Derin
  • Toner, Mehmet

Abstract

Provided herein are methods of intracellular delivery of a substance to one or more cells. The methods include providing a substrate defining a micro-channel in fluid communication with a first chamber and optionally in fluid communication with a second chamber, the micro-channel having a hydraulic diameter that is less than a hydraulic diameter of the first and second chambers; and driving a cell suspension through the micro-channel, thereby: i) causing the one or more cells to be stretched along a direction of flow and ii) inducing a formation of one or more temporary pores in a membrane of the one or more cells, wherein the cell suspension comprises the one or more cells, a polymer, and the substance. Also provided are systems for the intracellular delivery of a substance to one or more cells.

IPC Classes  ?

  • C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
  • C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

96.

Compositions and Methods for the Treatment and Diagnosis of Cancer

      
Application Number 18040935
Status Pending
Filing Date 2021-08-09
First Publication Date 2024-02-29
Owner
  • The General Hospital Corporation (USA)
  • BioVentures, LLC (USA)
Inventor
  • Li, Hong-Yu
  • Yan, Wei
  • Lan, Li

Abstract

Disclosed herein are RNA methyltransferase inhibitors and methods of using and making the same. The inhibitors may be used in a method for the treatment of a subject in need of a treatment for a cancer by administering an effective amount of the RNA methyltransferase inhibitor and an effective amount of a DNA damaging agent to the subject.

IPC Classes  ?

  • A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
  • A61K 33/243 - Platinum; Compounds thereof
  • A61P 35/00 - Antineoplastic agents

97.

MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR OVARIAN AND UTERINE ONCOPROTECTION, AND OVARIAN RESERVE AND UTERINE PRESERVATION

      
Application Number 18052485
Status Pending
Filing Date 2022-11-03
First Publication Date 2024-02-29
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Donahoe, Patricia K.
  • Pepin, David

Abstract

One aspect of the invention provides a method of ovarian protection by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). Ovarian protection can be an induced arrest of folliculogenesis to preserve fertility. In some embodiments, ovarian protection is oncoprotection, the protection of the ovarian function during a cytotoxic treatment, e.g., chemotherapy. Another aspect of the invention relates to a method of treating PCOS, the method comprising administering to a female subject a composition comprising recombinant MIS protein.

IPC Classes  ?

  • C07K 14/575 - Hormones
  • C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

98.

CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT

      
Application Number 18205293
Status Pending
Filing Date 2023-06-02
First Publication Date 2024-02-22
Owner The General Hospital Corporation (USA)
Inventor Elmaleh, David R.

Abstract

Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2 , or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

IPC Classes  ?

  • A61K 51/04 - Organic compounds
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
  • A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
  • C07D 311/24 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

99.

BIOORTHOGONAL LINKERS AND REACTIONS

      
Application Number 18247571
Status Pending
Filing Date 2021-10-04
First Publication Date 2024-02-22
Owner The General Hospital Corporation (USA)
Inventor
  • Carlson, Jonathan
  • Mikula, Hannes
  • Weissleder, Ralph

Abstract

The present disclosure provides bioorthogonal linkers and reagents, including trans-cyclooctene (“TCO”)- and tetrazine (“Tz”)-containing compounds. In a general aspect, the present disclosure provides reagents, conjugates, and bioactive molecules containing a trans-cyclooctene (“TCO”) fragment. Examples of TCO fragments include: Formulae (I) and (II). The present disclosure provides bioorthogonal linkers and reagents, including trans-cyclooctene (“TCO”)- and tetrazine (“Tz”)-containing compounds. In a general aspect, the present disclosure provides reagents, conjugates, and bioactive molecules containing a trans-cyclooctene (“TCO”) fragment. Examples of TCO fragments include: Formulae (I) and (II).

IPC Classes  ?

  • A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K 49/00 - Preparations for testing in vivo

100.

COMPOSITIONS FOR DETECTING SECRETION AND METHODS OF USE

      
Application Number 18446945
Status Pending
Filing Date 2023-08-09
First Publication Date 2024-02-22
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE BROAD INSTITUTE, INC. (USA)
Inventor
  • Burns, Sean
  • Wright, Jason
  • Sundberg, Thomas

Abstract

The present invention provides methods and compositions based on a non-naturally occurring nucleic acid construct encoding a fusion protein for quantitating levels of secretion in a single cell which may comprise a protein sequence which may comprise a cytoplasmic domain, a transmembrane domain and a vesicular domain, wherein the vesicular domain may comprise a protein tag sequence, wherein upon expression of the fusion protein by a cell, the fusion protein localizes to the membrane of a secretory vesicle such that the protein tag localizes to the lumen of the secretory vesicle, and wherein the protein tag binds to a cell-impermeable marker; whereby upon secretion of the contents of the secretory vesicle, the protein tag is exposed to the cell-impermeable marker, the fusion protein is recycled back into the cell, and the single cell becomes labeled with the marker relative to the amount of secretion.

IPC Classes  ?

  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • A61P 35/00 - Antineoplastic agents
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • G01N 21/64 - Fluorescence; Phosphorescence
  • G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  1     2     3     ...     21        Next Page